Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency
Abstract
Abstract Medulloblastoma is a biologically heterogeneous childhood cerebellar tumor harboring frequent chromatin-modifying gene alterations. How these alterations promote transcriptional programs governing malignancy remains poorly defined. To address this knowledge gap, we evaluated chromatin states across medulloblastoma subgroups by multi-modal integration of histone modifications with mutational, DNA methylation and transcriptomic profiles. A bivalent/poised enhancer (EnhBiv) state was specifically enriched at the promoters of neurodevelopmental genes in Group 3/4 medulloblastoma. Integrative bioinformatics coupled with chromatin occupancy studies identified aberrant KDM2B binding at EnhBiv-enriched promoters. CRISPR-mediated knockout or acute protein degradation of KDM2B selectively suppressed the growth of medulloblastoma models in vitro and in vivo. Mechanistically, KDM2B promotes sequential recruitment of Polycomb repressive complexes (PRC1/PRC2) and EnhBiv chromatin, thereby repressing neuronal differentiation programs. Collectively, we provide foundational insights into an epigenetic basis of medulloblastoma, nominating KDM2B as a selective dependency in high-risk subgroups that warrants consideration as a candidate therapeutic target.
// Source
Authors: Ran Tao, Serap Erkek, Beisi Xu, Yurika Matsui, Priya Mittal, Kyle S. Smith, Yiran Li, David Filipovic, Ruijie Xu, Qingsong Gao, Emily Darrow, Rahul Kumar, Mohamed Nadhir Djekidel, Richa Bajpai, Jennifer L. Hadley, Melissa Batts, Sara A. Lewis, Taha Soliman, Colleen A. Reilly, Natarajan V. Bhanu, Leena Paul, Hong Lin, Brian Gudenas, Kim Lowe, Marc Zapatka, Laura Sieber, David Jones, Marcel Kool, Sebastian M. Waszak, Volker Hovestadt, Ivo Buchhalter, Marina Ryzhova, Andrey Korshunov, Peter Lichter, Lukas Chávez, Lena M. Kutscher, Benjamin Aaron Garcia, Shondra M. Pruett‐Miller, Xin Zhou, Brent A. Orr, Giles W Robinson, Gang Wu, Jan O. Korbel, Jamy C. Peng, Stefan M. Pfister, Paul A. Northcott
Institutions: University of California San Diego, Heidelberg University, University Hospital Heidelberg, Washington University in St. Louis, WinnMed, German Cancer Research Center, Broad Institute, Dana-Farber Cancer Institute, Mayo Clinic, Izmir University, University Medical Center Utrecht, Deutsches Konsortium für Translationale Krebsforschung, National Center for Tumor Diseases, Discovery Institute, St. Jude Children's Research Hospital, Hopp Children's Cancer Center Heidelberg, Princess Máxima Center, Sanford Burnham Prebys Medical Discovery Institute, European Molecular Biology Laboratory, Children’s Institute, Burdenko Neurosurgery Institute, Rady Children's Institute for Genomic Medicine